Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas (Q64397654)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas |
clinical trial |
Statements
Bretuximab (English)
0 references
A Phase II Study of Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas (English)
0 references
25 March 2016
0 references
August 2018
0 references
25
0 references
18 year
0 references